SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
ZBH
--
0.00%
--
Zimmer Biomet Holdings Inc (ZBH): Are Hedge Funds Right Dumping This Stock?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain
Insider Monkey · 6d ago
Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid
Zacks · 6d ago
Needham weighs top picks as med techs recover
News is free at Seeking Alpha. This post is a Notable Call. Notable Calls are a Premium feature. To access this and other Notable Calls, try a free trial t
seekingalpha · 05/29 03:57
Conformis Announces Settlement Of Patent Dispute With Zimmer Biomet Holdings
Conformis and Zimmer Biomet settled disputes related to Patient-Specific Instrument Patents for Use with Off-the-Shelf Knee, Hip, and Shoulder Implants BILLERICA, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc.
Benzinga · 05/28 11:33
Zimmer Biomet Holdings to Present at Goldman Sachs 41st Annual Global Healthcare Conference
PR Newswire · 05/27 12:00
Hospitals Reopening, But Zimmer Biomet Needs To Stabilize Its Knee Business
Seeking Alpha - Article · 05/22 12:58
Zimmer Biomet Holdings, Inc. -- Moody's announces completion of a periodic review of ratings of Zimmer Biomet Holdings, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Zimmer Biomet Holdings, Inc. New York, May 19, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Zimmer Biomet Holdi
Moody's · 05/19 19:58
JMP Securities Maintains Market Outperform on Zimmer Biomet Holdings, Lowers Price Target to $150
JMP Securities maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Market Outperform and lowers the price target from $175 to $150.
Benzinga · 05/18 14:43
Insider Purchases That Could Outperform - Weekly Update (05/08/20 - 05/14/20)
Seeking Alpha - Article · 05/17 17:03
Health-Care Stocks Popular With ESG Funds Outperform
marketwatch.com · 05/16 09:15
Zimmer Biomet Holdings: 22% Upside Potential
Seeking Alpha - Article · 05/14 12:34
"Stay at Home" Stocks Still Rule the Roost as Nvidia, Microsoft, Apple Start Week Firmly
Benzinga · 05/12 21:11
UBS Maintains Buy on Zimmer Biomet Holdings, Lowers Price Target to $165
UBS maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and lowers the price target from $180 to $165.
Benzinga · 05/12 16:37
Canaccord Genuity Maintains Buy on Zimmer Biomet Holdings, Raises Price Target to $137
Canaccord Genuity maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and raises the price target from $135 to $137.
Benzinga · 05/12 16:21
Citigroup Maintains Buy on Zimmer Biomet Holdings, Raises Price Target to $140
Citigroup maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and raises the price target from $125 to $140.
Benzinga · 05/12 15:28
Stifel Maintains Buy on Zimmer Biomet Holdings, Raises Price Target to $130
Stifel maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and raises the price target from $111 to $130.
Benzinga · 05/12 14:20
SunTrust Robinson Humphrey Maintains Buy on Zimmer Biomet Holdings, Raises Price Target to $132
SunTrust Robinson Humphrey maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and raises the price target from $125 to $132.
Benzinga · 05/12 13:42
Deutsche Bank Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $146
Deutsche Bank analyst Pito Chickering maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and lowers the price target from $160 to $146.
Benzinga · 05/12 13:12
Wells Fargo Maintains Overweight on Zimmer Biomet Holdings, Raises Price Target to $132
Wells Fargo maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Overweight and raises the price target from $124 to $132.
Benzinga · 05/12 12:31
Oppenheimer Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $138
Oppenheimer maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Outperform and lowers the price target from $141 to $138.
Benzinga · 05/12 12:24